62 results about "Staphylococcus aureus infections" patented technology

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention is applicable to the technical field of genetic engineering, and provides a vaccine for preventing and treating staphylococcus aureus mastitis and application of the vaccine. A recombinant bacillus subtilis construction method comprises the following steps: taking a DNA sequence as shown in SEQ ID NO.3 as a template, and performing PCR amplification to obtain a PCR product sequence; connecting the PCR product to a pHT43 vector, and converting the pHT43 vector into a competent cell DH5alpha, so as to obtain a recombinant plasmid pHT43-cCsa; the method comprises the following steps: transforming a recombinant plasmid pHT43-cCsa into a competent cell of bacillus subtilis WB800N, taking pHT43-F and pHT43-R as primers, and screening a positive transformant through a PCR (Polymerase Chain Reaction) technology; the recombinant bacillus subtilis for expressing the staphylococcus aureus Csa protein is constructed by utilizing a homologous recombination technology, so that pathological injury caused by staphylococcus aureus infection can be reduced, and staphylococcus aureus mastitis of dairy cattle can be prevented.

The invention discloses antibiotic-free hydrogel for nursing staphylococcus aureus infection as well as a preparation method and application of the antibiotic-free hydrogel. The hydrogel is prepared from metal ion compounds such as zinc ions, copper ions and iron ion compounds, a natural high polymer material and an antioxidant as raw materials, and has the advantages of efficient antibacterial property, high safety, long-acting slow release and the like. An in-vitro antibacterial experiment shows that the sterilizing rate of the metal ion compound on staphylococcus aureus can reach 90%-99.9%; animal experiments prove that the hydrogel can effectively relieve inflammatory reaction of infected parts, and skin irritation experiments show that the product is free of irritation and anaphylactic reaction. The invention provides a safe and effective nonreactive solution for nursing of staphylococcus aureus infection.

The application belongs to the field of antibacterial two-dimensional nanomaterial Mxene catalysts, and particularly relates to a monolayer W@MoS2 nanosheet as well as a preparation method and application thereof. The method comprises the following steps: 1) dissolving water-soluble molybdate and water-soluble tungstate in water to obtain a mixed solution; 2) adding a sulfur source and an organic solvent to the mixed solution, and then performing reaction after mixing, and drying to obtain a powder. The monolayer W@MoS2 nanosheet has a unique two-dimensional planar structure, a large specific surface area, and good optical and electronic properties, and has high light-heat absorption in the near-infrared two region, i.e., the light-heat conversion efficiency is improved. Meanwhile, the peroxidase-like activity of the monolayer W@MoS2 nanosheet material realizes efficient light-heat amplification, can treat methicillin-resistant Staphylococcus aureus infection, and avoids heat therapy damage to normal tissues.

The invention relates to the technical field of medicine synthesis, and particularly discloses an aminoguanidine tetralone derivative and a structural general formula of the aminoguanidine tetralone derivative. The invention also discloses a preparation method and application of the derivative. The aminoguanidine tetralone derivative has a good inhibiting and killing effect on staphylococcus aureus and can be used for preventing and treating diseases caused by staphylococcus aureus infection.

The invention relates to a PPP2CB phosphatase target small molecule compound and application thereof, and belongs to the field of biological medicine. The invention provides a small molecule compound C16H16N4O, which is specifically combined with a PPP2CB catalytic subunit, and by enhancing the activity of PPP2CB phosphatase, the serine / threonine phosphorylation level of ERK, MAPK, JAK and other kinases in macrophages is remarkably reduced, and the activation of NF-kappa B, JAK-STAT and MAPK-ERK inflammation signal pathways is blocked. The compound is suitable for treating inflammatory storm caused by SARS-CoV-2, influenza virus and staphylococcus aureus infection. In an SARS-CoV-2 infection model, the survival rate of the mice is increased from 0 to 50%; the lung pathological injury is relieved after influenza virus infection. Sepsis caused by staphylococcus aureus USA300 is effectively inhibited, and the death rate is reduced. The clinical transformation potential is realized.

The present invention relates to a series of cell wall degrading enzymes with antibacterial activity for effectively controlling Staphylococcus aureus, and the cell wall degrading enzymes with antibacterial activity of the present invention are a series of lyases with new amino acid sequences. The cell wall degrading enzymes with antibacterial activity of the present invention can be used as agents capable of effectively inhibiting Staphylococcus aureus, and can be applied to the disinfection of Staphylococcus aureus in the environment and the treatment of diseases caused by Staphylococcus aureus infection, etc.

The present invention discloses an mRNA encoding an anti-Staphylococcus aureus enterotoxin B antibody and an application thereof. The mRNA comprises an mRNA encoding a light chain of the anti-Staphylococcus aureus enterotoxin B antibody and an mRNA encoding a heavy chain of the anti-Staphylococcus aureus enterotoxin B antibody, wherein the optimized base sequences of the variable regions CDR1, CDR2 and CDR3 of the heavy chain are shown as SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, respectively; and the optimized base sequences of the variable regions CDR1, CDR2 and CDR3 of the light chain are shown as SEQ ID NO.7, SEQ ID NO.8 and SEQ ID NO.9. The antibody can be used to neutralize SEB toxin and simultaneously prevent and treat Staphylococcus aureus infection.

The present invention discloses four quaternary ammonium salt derivatives, their synthesis methods, and applications. One quaternary ammonium salt derivative of the present invention has the chemical name (E)-N,N,N-trimethyl-1-(4-(phenyldiazenyl)phenyl)methylammonium bromide (Compound 1e). Compound 1e, synthesized using aniline as a starting material, exhibits excellent antibacterial activity against Staphylococcus aureus at 500 μg / mL.

The application discloses an antibody against Staphylococcus aureus IsdB and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are respectively shown as SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11. In addition, the application further discloses a product for detecting Staphylococcus aureus IsdB and application of the antibody in preparation of a diagnosis, prevention and / or treatment of diseases related to Staphylococcus aureus infection. The application provides a new idea for detection of Staphylococcus aureus IsdB and treatment of related diseases, and has a wide application prospect.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

The invention relates to the technical field of nano-medicine carriers, in particular to composite drug-loaded nanoparticles based on acylated polysaccharide and berberine as well as a preparation method and application of the composite drug-loaded nanoparticles. The preparation method comprises the following steps: carrying out acylation modification on natural polysaccharide by using a basic catalyst and acid anhydride to obtain acylated natural polysaccharide; wherein the acylation modification mode comprises acetylation modification or propionylation modification; in an organic solvent, the berberine and the acylated natural polysaccharide are subjected to encapsulation treatment, and the composite drug-loaded nanoparticles based on the acylated polysaccharide and the berberine are obtained. According to the preparation method, the natural polysaccharide is subjected to acylation modification, the hydrophobicity of the natural polysaccharide is adjusted, and the encapsulation efficiency of berberine is remarkably improved. On one hand, the composite drug-loaded nanoparticles can significantly improve the bioavailability of berberine and prolong the in-vivo action time of berberine, and on the other hand, the composite drug-loaded nanoparticles can promote the repair and healing of wounds infected by staphylococcus aureus and reduce the drug resistance of staphylococcus aureus.

The application discloses an antibacterial peptide derived from the skin of bullfrog and application thereof, and the amino acid sequence of the antibacterial peptide is GSVGPVGPR (as shown in SEQ ID NO:1), and the molecular weight is 824.4504 g / mol. The antibacterial peptide has obvious inhibiting effect on Staphylococcus aureus, and can be used for preparing a medicine for preventing or inhibiting Staphylococcus aureus infection. Meanwhile, the antibacterial peptide and vitamin A have a significant synergistic bactericidal effect on Staphylococcus aureus. The antibacterial peptide and vitamin A can significantly reduce the use concentration of single component, improve the antibacterial efficiency, overcome the bacterial drug resistance problem, and can be used for preparing antibacterial medicines, skin external preparation, medical dressings, feed additives and food preservatives.

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.

The invention discloses a preparation method of a phenol derivative capable of effectively inhibiting staphylococcus aureus, and belongs to the technical field of synthesis and application of medical intermediates. The preparation method comprises the following steps: under the conditions of protective atmosphere and illumination, carrying out an addition reaction on 4-benzal-2, 6-di-tert-butylcyclohexane-2, 5-diene-1-ketone and cyclohexane under the action of 4-nitrophthalonitrile, so as to obtain the 2, 6-di-tert-butyl-4-(cyclohexyl (phenyl) methyl) phenol. The preparation method has the advantages of simplicity in operation, mild reaction conditions, low cost of used reagents, high yield and the like, is favorable for realizing large-scale production, provides a key intermediate support for developing low-cost and high-activity anti-staphylococcus aureus drugs, and has important significance in relieving clinical drug-resistant staphylococcus aureus infection treatment dilemma.

The invention discloses an application of a photostable pyridine fused Norcorrole nickel (II) dimer in treatment of staphylococcus aureus infection, and belongs to the technical field of medicines. The efficient antibacterial performance of the anti-aromaticity compound Ni (II)-PyNc2 under NIR irradiation is proved, the PCE of the anti-aromaticity compound Ni (II)-PyNc2 reaches 73%, and the temperature rises to 56 DEG C after the anti-aromaticity compound Ni (II)-PyNc2 is irradiated for 6 minutes. Through in-vitro and in-vivo experiments, Ni (II)-PyNc2 shows excellent light stability, biological membrane inhibition capability and wound healing promotion effect, and has good biocompatibility. The material is expected to become an ideal candidate for clinical photo-thermal therapy.

The application belongs to the technical field of microorganisms, and discloses application of shikimic acid in preparation of antibacterial preparations for inhibiting staphyloxin synthesis. It is found that shikimic acid can inhibit synthesis of staphyloxin in methicillin-resistant Staphylococcus aureus (MRSA), reduce tolerance of the bacteria to oxidative stress, induce accumulation of intracellular active oxygen, and damage cell membrane structure and function, including reducing cell membrane order, inducing membrane depolarization, increasing membrane permeability, and leading to ATP leakage and energy metabolism disorder. A new strategy and preparation direction are provided for clinical treatment of multi-drug resistant Staphylococcus aureus infection, and the application has important theoretical value and application prospect.

The invention discloses a manganese-based nano-enzyme preparation method, a manganese-based nano-enzyme product and an application of the manganese-based nano-enzyme product in antibiosis, and belongs to the technical field of nano-enzymes and biomedicine nanotechnology. According to the preparation method, KMnO4 and C18H34O2 are used as raw materials, and the manganese-based nano-enzyme is prepared through a water phase method. The nano-enzyme shows good application prospects in removing bacterial biofilms, inhibiting bacteria from forming biofilms and treating wound infection models. Animal experiments show that the hydrogel has excellent biocompatibility, is free of toxic accumulation, and can effectively treat mouse wound staphylococcus aureus infection and promote wound healing.

The invention discloses a transgenic animal antibody high-yield expression system based on double-copy site-specific integration and application of the transgenic animal antibody high-yield expression system. According to the invention, dual-copy anti-staphylococcus aureus enterotoxin B (SEB) monoclonal antibody genes are integrated at safe sites of mouse ROSA26 and H11 in a targeting manner, so that the whole-body high-level stable expression of the antibody in a mouse body is realized, and the yield and neutralizing activity of the antitoxin antibody are remarkably improved. The invention provides a new thought and a new strategy for the development of a low-cost and high-efficiency therapeutic antibody bioreactor. Besides, the constructed SEB antibody gene animal model provides an important tool for research on staphylococcus aureus infection resistance, provides a potential model animal solution for disease prevention and control of animal husbandry, and has good application value and industrial transformation prospect.

The present invention discloses the use of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of medical technology. Ferrous ions were used in antibacterial activity tests on Staphylococcus aureus, demonstrating a strong bactericidal effect. When sterilizing Staphylococcus aureus, the survival rate was less than 0.001%, and when sterilizing methicillin-resistant Staphylococcus aureus (MRSA), the survival rate was less than 0.01%. The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA lung infection and effectively and timely prevented the reproduction and spread of microorganisms in the body. This indicates that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention particularly discloses application of a lactylation inhibitor in preparation of a medicine for treating staphylococcus aureus biofilm related infection, and relates to the technical field of biological medicine. The invention provides application of a SarA protein K72 site lactic acid inhibitor in preparation of a medicine for preventing and / or treating staphylococcus aureus infection of diabetic patients, and discloses that high glucose promotes formation of a staphylococcus aureus biofilm through lactic acid modification on a SarA K72 site.

The invention relates to the field of biological medicine and immunology, in particular to preparation and application of an anti-staphylococcus aureus enterotoxin B antibody. A heavy chain variable region of the antibody SEB-A8 provided by the invention comprises CDR sequences as shown in SEQ ID NO: 1-3, a light chain variable region of the antibody SEB-A8 comprises CDR sequences as shown in SEQ ID NO: 9-11, and the antibody SEB-A8 has important application value in treatment, prevention or diagnosis of staphylococcus aureus infection. Experimental data show that the antibody can effectively neutralize the superantigen activity of SEB and significantly improve the survival rate of MRSA infected mice, has a dose-dependent protection effect, can be used as a non-antibiotic treatment strategy, is used for treatment of methicillin-resistant staphylococcus aureus infection, has great significance in controlling development of bacterial drug resistance, and has a broad application prospect. And a new research direction is provided for clinical anti-infection treatment.

The invention discloses a covalent organic framework polymer capable of selectively inactivating staphylococcus aureus and application of the covalent organic framework polymer. The covalent organic framework polymer is obtained by polymerization of a ruthenium complex and heteropoly acid through aminal reaction, and the ruthenium complex is bis (hexafluorophosphate) tris (5, 5 '-bis (diethoxymethyl)-2, 2'-dipyridyl) ruthenium; the preparation method comprises the following steps: adding bis (hexafluorophosphate) tris (5, 5 '-bis (diethoxymethyl)-2, 2'-dipyridyl) ruthenium and Tris-V6O19 into an organic solvent, and carrying out solvothermal reaction, so as to obtain the covalent organic framework polymer. The m-RuV-COF prepared by the invention can selectively inactivate staphylococcus aureus at an extremely low concentration, and has a very small inactivation effect on escherichia coli. And a new effective strategy is provided for specifically solving the problem of staphylococcus aureus infection.

The invention discloses a staphylococcus aureus MntC protective epitope peptide, an epitope vaccine as well as a preparation method and application of the staphylococcus aureus MntC protective epitope peptide and the epitope vaccine, the protective B cell epitope peptide Loop101 of a staphylococcus aureus MntC antigen is obtained, the novel epitope vaccine MntC101 is successfully constructed based on the epitope, after the vaccine is inoculated, an anti-Loop101 antibody can be efficiently induced in SPF and staphylococcus aureus pre-infected mice, and the staphylococcus aureus MntC protective epitope peptide and the novel epitope vaccine MntC101 can be used for preparing the staphylococcus aureus MntC protective epitope peptide. SPF and pre-infected mice can be effectively protected from being infected with staphylococcus aureus, and the method has a good application prospect.

Cloxacillin Sodium is an organic compound with the molecular formula C 19 H 18 Cl2N3NaO6S. It is a white powder or crystalline powder; slightly smelly and bitter; hygroscopic. Cloxacillin sodium is prepared into an injection for administration, which is mainly used to treat penicillinase-producing Staphylococcus aureus infections, including sepsis, endocarditis, pneumonia, and skin and soft tissue infections. Because it has multiple easily hydrolyzed groups, such as β-lactam rings and amide bonds, it has poor stability and is easily hydrolyzed. In order to improve the stability of cloxacillin sodium, the present invention uses Bicine (N,N-bis(hydroxyethyl)glycine) as a buffer salt and CMC / AA / AM as a hygroscopic agent (carboxymethyl cellulose (CMC) connected to acrylic acid (AA) connected to acrylamide (AM)), and adopts a sterile packaging process to obtain a highly stable cloxacillin sodium preparation.

The invention discloses an antigen protein as well as a preparation method and application thereof. The antigen protein comprises a soluble catalytic domain of the membrane protein LCP or a variant thereof. The antigen protein can be used for preventing and treating staphylococcus aureus infection, especially drug-resistant bacteria infection, and clinical related infectious diseases caused by the staphylococcus aureus infection, so that more stable broad-spectrum protection on staphylococcus aureus infection, especially drug-resistant staphylococcus aureus, is realized.

The application provides a staphylococcus aureus toxin LukG antigen epitope peptide, comprising a polypeptide with an amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 40 or SEQ ID NO: 42, and the application also provides application of the antigen epitope peptide in preparation of a staphylococcus aureus infection diagnostic, preventive or therapeutic product. The application determines a staphylococcus aureus toxin LukG antibody dominant epitope peptide through screening, and the staphylococcus aureus toxin LukG antibody dominant epitope peptide has strong immunogenicity and can be used for staphylococcus aureus infection diagnosis, prevention or treatment.

The present application relates to the application of Staphylococcus aureus toxin protein related gene SA1833 / SA1832 in treating Staphylococcus aureus infection. Specifically, it relates to the application of Staphylococcus aureus toxin protein related gene SA1833 and / or SA1832 as a target in the preparation of a drug for treating drug-resistant Staphylococcus aureus infection, preferably, the drug resistance is preferably methicillin resistance. With SA1833 and / or SA1832 as a target, the clinical treatment of repeated and persistent infection caused by methicillin-resistant Staphylococcus aureus retention has a significant effect. It provides a new target for the development of drugs for treating repeated infection caused by clinical MRSA strains, provides more choices for the treatment of Staphylococcus aureus, and has a wide application prospect.